Key facts
- It has raised $32.4M; the latest was Later Stage VC ($5.6M) in Jul 2025.
- Notable investors include Boston Consulting Group, DIG Investment, Sanner Ventures, Aeternum Capital, Albonja — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for OnDosis
- ·The full record, as it builds
Funding rounds
No funding rounds for OnDosis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OnDosis
Developer of a personalized medicine device intended to improve how patients manage and take medications. The company offers a dosage manager supporting flexible delivery of pellets, granules, mini tablets, and powders with integrated digital technologies and IoT connectivity, enabling patients and healthcare providers to achieve precise dosing and enhanced treatment management.
- Sector
- Healthcare
- HQ
- Molndal, Sweden
- Founded
- 2017
- Employees
- 22
- Website
- ondosis.com/
- Ownership
- Privately Held (backing)
OnDosis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OnDosis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OnDosis in its N-PORT filings yet. We sweep new filings monthly.